Lipella Pharmaceuticals announced the dosing of the first two patients with LP-310 in its Phase 2a clinical trial in Oral Lichen Planus, or OLP, patients.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LIPO: